Next |
home / stock / arvn / arvn message board
Subject | By | Source | When |
---|---|---|---|
ARVN up 138% > Based on data to | crudeoil24 | investorshub | 12/14/2020 2:19:37 PM |
Advantages of PROTACs vs. inhibition... | biocqr | investorshub | 12/17/2019 3:29:22 PM |
Idk about that, I thought it had some | G-lupo | investorshub | 11/29/2019 5:15:41 AM |
Starting to see a chink in the armor! | boo boo | investorshub | 11/26/2019 10:04:01 PM |
Possibly wall at 30.50 | G-lupo | investorshub | 11/15/2019 10:01:32 PM |
I feel people are going to start taking | G-lupo | investorshub | 11/14/2019 6:08:24 PM |
The offering: | boo boo | investorshub | 11/14/2019 3:19:51 PM |
Benzinga 11/14/2019: | boo boo | investorshub | 11/14/2019 3:05:47 PM |
It doesn't have to be a PR: | boo boo | investorshub | 11/13/2019 5:53:07 PM |
Thanks, Im in it, thought $28 would be | G-lupo | investorshub | 11/13/2019 5:47:45 PM |
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-fro | boo boo | investorshub | 11/13/2019 4:11:25 PM |
When did they Do a price target announcement? | G-lupo | investorshub | 11/13/2019 4:03:44 PM |
If I were in this one (I'm not), | boo boo | investorshub | 11/13/2019 3:14:32 PM |
Arvn looking good, defintely see $26-27 | G-lupo | investorshub | 11/05/2019 10:05:43 PM |
What you mean IBD? | G-lupo | investorshub | 10/29/2019 3:53:07 PM |
Not me. I look for the trade | boo boo | investorshub | 10/29/2019 3:12:40 PM |
I agree I own a decent amount, purchased | G-lupo | investorshub | 10/29/2019 3:05:40 PM |
Missing a trade and people who post a | boo boo | investorshub | 10/29/2019 2:06:03 PM |
What are you talking about ? Saw the | G-lupo | investorshub | 10/29/2019 1:30:45 AM |
Screwed this one up. More and better | boo boo | investorshub | 10/25/2019 8:07:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...